ANNX - NASDAQ
Annexon, Inc.
$5.39
+2.5%Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
At a Glance
Live Snapshotannx
Cash at End of Period
Last Annual Value
163.08M
3-Year CAGR
5%
5-Year CAGR
-9%
10-Year CAGR
49%
Annexon, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Annexon, Inc. NASDAQ:ANNX | 163.08M | -10.3% | 16.9% | N/A | |
 DiaMedica Therapeutics Inc. NASDAQ:DMAC | 15.65M | 51.0% | 27.2% | 24.6% | |
 Alector, Inc. NASDAQ:ALEC | 67.65M | -3.8% | -27.2% | 2.9% | |
75.60M | 69.5% | 74.8% | N/A | ||
 Editas Medicine, Inc. NASDAQ:EDIT | 149.31M | 5.4% | -6.4% | -2.1% | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | 61.77M | -24.9% | -26.8% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 100.97M | 29.6% | 21.2% | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 112.82M | -8.7% | -9.3% | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 124.64M | 52.4% | 10.2% | N/A | |
 Altimmune, Inc. NASDAQ:ALT | 43.80M | -31.3% | -25.5% | -11.8% | |
 Korro Bio, Inc. NASDAQ:KRRO | 25.23M | -47.4% | -21.4% | N/A |
Annexon, Inc. Fair Value Envelope
Related Guides
Continue your ANNX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.